A record number of products still under development in the life sciences sector continue to provide tailwinds for the industry, despite volatility in the broader macroeconomic environment, says Matt Gardner, CBRE’s U.S. life sciences leader.
Speaking on the Nareit REIT Report, Gardner noted that a bull run of investment in life sciences, that started in 2015, “left us with an incredible number of products in development. And those are still there.”
Gardner stressed that the life sciences industry doesn’t follow broader economic patterns. “If a product takes 10 to 15 years to develop, the investment in that product isn't going to follow a seven year economic cycle, which is why we look at this record number of products in phase two and phase three clinical trials as such an important sign of the industry's overall wellbeing. The science is still there,” he said.
Nareit's REIT Report Podcast